Pfizer's experimental obesity drug, acquired through Metsera, has shown promising results in a mid-stage trial. The injectable treatment, when taken once a month, led to significant weight loss in patients with obesity or who were overweight. The study revealed that patients lost up to 12.3% of their weight compared to a placebo at week 28, and up to 10.5% overall, regardless of discontinuations. This is a major breakthrough, as it suggests that the injection can be administered less frequently than existing drugs without compromising its effectiveness. Pfizer's ultra-long-acting GLP-1 drug, PF'3944, is engineered to remain active in the body for longer than current treatments like Novo's Wegovy. The company plans to advance 10 phase three trials on this injection this year, aiming to enter a market dominated by Eli Lilly and Novo Nordisk. However, the drug's potential to revolutionize obesity treatment is still a subject of debate, as some experts question its long-term efficacy and safety. 'These topline results ... reinforce the potential of PF'3944 as a monthly treatment with competitive efficacy,' said Dr. Jim List, Pfizer's chief internal medicine officer. But here's where it gets controversial... Could this be the future of obesity treatment? Or are there hidden risks we need to consider? What do you think? Share your thoughts in the comments below.
